Related Experiment Videos
Inflammatory bowel disease and osteoporosis
H Andreassen1, J Rungby, J F Dahlerup
1Dept. of Internal Medicine, Roskilde Amtssygehus, Køge, Denmark.
Scandinavian Journal of Gastroenterology
|January 23, 1998
Summary
Inflammatory bowel disease (IBD) is linked to over 50% prevalence of low bone mass. Corticosteroids may cause this bone disease, necessitating further research into prevention and treatment strategies.
Area of Science:
- Gastroenterology
- Endocrinology
- Rheumatology
Background:
- Inflammatory bowel disease (IBD) is increasingly associated with osteoporosis.
- Over 50% of IBD patients exhibit low bone mass, a significant clinical concern.
- Corticosteroids are implicated as a major factor in IBD-related bone disease.
Purpose of the Study:
- To review current knowledge on the mechanisms and epidemiology of bone disease in IBD patients.
- To highlight the prevalence and diagnostic tools for osteoporosis in IBD.
- To discuss scarce findings on prevention and treatment of IBD-related osteoporosis.
Main Methods:
- Literature review of studies on inflammatory bowel disease and bone disease.
- Analysis of epidemiological data and etiological factors, including corticosteroid use.
- Evaluation of available evidence on diagnostic methods like dual-energy X-ray absorptiometry.
Main Results:
- High prevalence of low bone mass (over 50%) in patients with inflammatory bowel disease.
- Corticosteroid therapy identified as a potential primary cause of bone disease in IBD.
- Limited studies on prevention and treatment, with hormone replacement therapy and calcium/vitamin D supplementation showing promise.
Conclusions:
- IBD poses a significant risk for osteoporosis, requiring vigilant monitoring and management.
- Further research is crucial to elucidate the exact mechanisms and develop effective prevention/treatment strategies for IBD-related bone disease.
- Non-invasive diagnostic tools like DEXA are vital for early detection and intervention.